ARTICLE | Clinical News

Sirukumab: Additional Ph III SIRROUND-T data

November 18, 2016 6:21 PM UTC

Additional data from the double-blind, international Phase III SIRROUND-T (CNTO136ARA3003) trial in 878 patients with moderately to severely active RA who were unresponsive or intolerant to anti-tumor...

BCIQ Company Profiles

GSK plc

Johnson & Johnson

BCIQ Target Profiles

Interleukin-6 (IL-6)